As global biotech investment patterns shift, investors are turning their eyes to Asia-Pacific. While China remains a powerhouse, emerging hubs like Singapore and South Korea are quickly gaining attention for their political stability, strong IP protection, and innovation-friendly policies.
Why are APAC biotech markets suddenly so appealing to investors? And how are these emerging hubs reshaping the future of global biotech innovation?
On Wealth Tracker, Hongbin Jeong speaks to Fabio La Mola, Partner at Bain & Company, to find out more.

The Big Story: Trump’s prime-time address on Iran - Victory speech or unfinished war?
19:57

Wealth Tracker: If investors aren’t selling US assets, where is the ‘Sell America’ trade happening?
18:10

What's Trending: China's laser highways are real… and Gmail is finally letting you change your cringe email
16:32